A review of challenges and prospects of 3D cell-based culture models used for studying drug induced liver injury during early phases of drug development - PubMed

Affiliations

• PMID: 36879529
• DOI: 10.1177/09603271221147884

Free article

Review

A review of challenges and prospects of 3D cell-based culture models used for studying drug induced liver injury during early phases of drug development

John K Chipangura et al. Hum Exp Toxicol. 2023 Jan-Dec.

Free article

Abstract

Drug-induced liver injury (DILI) is the leading cause of compound attrition during drug development. Over the years, a battery of in-vitro cell culture toxicity tests is being conducted to evaluate the toxicity of compounds prior to testing in laboratory animals. Two-dimensional (2D) in-vitro cell culture models are commonly used and have provided a great deal of knowledge; however, these models often fall short in mimicking natural structures of tissues in-vivo. Testing in humans is the most logical method, but unfortunately there are ethical limitations associated with human tests. To overcome these limitations better human-relevant, predictive models are required. The past decade has witnessed significant efforts towards the development of three-dimensional (3D) in-vitro cell culture models better mimicking in-vivo physiology. 3D cell culture has advantages in being representative of the interactions of cells in-vivo and when validated can act as an interphase between 2D cell culture models and in-vivo animal models. The current review seeks to provide an overview of the challenges that make biomarkers used for detection of DILI not to be sensitive enough during drug development and explore how 3D cell culture models can be used to address the gap with the current models.

Keywords: 3D cell culture; In-vitro; In-vivo; drug induced liver injury; liver biomarkers.

Similar articles

• Development of novel tools for the in vitro investigation of drug-induced liver injury.

  Jiang J, Wolters JE, van Breda SG, Kleinjans JC, de Kok TM. Jiang J, et al. Expert Opin Drug Metab Toxicol. 2015;11(10):1523-37. doi: 10.1517/17425255.2015.1065814. Epub 2015 Jul 9. Expert Opin Drug Metab Toxicol. 2015. PMID: 26155718 Review.

• Current limitations and future opportunities for prediction of DILI from in vitro.

  Funk C, Roth A. Funk C, et al. Arch Toxicol. 2017 Jan;91(1):131-142. doi: 10.1007/s00204-016-1874-9. Epub 2016 Oct 20. Arch Toxicol. 2017. PMID: 27766365 Review.

• Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials.

  Tutty MA, Movia D, Prina-Mello A. Tutty MA, et al. Drug Deliv Transl Res. 2022 Sep;12(9):2048-2074. doi: 10.1007/s13346-022-01147-0. Epub 2022 May 4. Drug Deliv Transl Res. 2022. PMID: 35507131 Free PMC article. Review.

• Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro.

  Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, Roth AB. Nguyen DG, et al. PLoS One. 2016 Jul 7;11(7):e0158674. doi: 10.1371/journal.pone.0158674. eCollection 2016. PLoS One. 2016. PMID: 27387377 Free PMC article.

• Role of three-dimensional cell culture in therapeutics and diagnostics: an updated review.

  Biju TS, Priya VV, Francis AP. Biju TS, et al. Drug Deliv Transl Res. 2023 Sep;13(9):2239-2253. doi: 10.1007/s13346-023-01327-6. Epub 2023 Mar 27. Drug Deliv Transl Res. 2023. PMID: 36971997 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal